"Receptors, Neurokinin-3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of cell surface receptors for tachykinins that prefers neurokinin B (neurokinin beta, neuromedin K) over other tachykinins. Neurokinin-3 (NK-3) receptors have been cloned and are members of the G-protein coupled receptor superfamily. They have been found in the central nervous system and in peripheral tissues.
MeSH Number(s)
D12.776.543.750.720.600.830.580
D12.776.543.750.750.555.830.580
Concept/Terms
Receptors, Neurokinin-3- Receptors, Neurokinin-3
- Receptors, Neurokinin 3
- Receptors, Neuromedin K
- K Receptors, Neuromedin
- Neuromedin K Receptors
- Neurokinin B Receptors
- B Receptors, Neurokinin
- Receptors, Neurokinin B
- NK-3 Receptor
- NK 3 Receptor
- Receptor, NK-3
- Receptors, NK-3
- Receptors, NK 3
- Neurokinin-3 Receptor
- Neurokinin 3 Receptor
- Receptor, Neurokinin-3
- Neurokinin-3 Receptors
- Neurokinin 3 Receptors
- Neuromedin K Receptor
- Receptor, Neuromedin K
- NK-3 Receptors
- NK 3 Receptors
Below are MeSH descriptors whose meaning is more general than "Receptors, Neurokinin-3".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Neurotransmitter [D12.776.543.750.720]
- Receptors, Neuropeptide [D12.776.543.750.720.600]
- Receptors, Tachykinin [D12.776.543.750.720.600.830]
- Receptors, Neurokinin-3 [D12.776.543.750.720.600.830.580]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Neuropeptide [D12.776.543.750.750.555]
- Receptors, Tachykinin [D12.776.543.750.750.555.830]
- Receptors, Neurokinin-3 [D12.776.543.750.750.555.830.580]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Neurokinin-3".
This graph shows the total number of publications written about "Receptors, Neurokinin-3" by people in Harvard Catalyst Profiles by year, and whether "Receptors, Neurokinin-3" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 4 | 0 | 4 |
| 2013 | 1 | 2 | 3 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 2 | 4 |
| 2016 | 2 | 1 | 3 |
| 2017 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
Below are the most recent publications written about "Receptors, Neurokinin-3" by people in Profiles.
-
Functional Rescue of Inactivating Mutations of the Human Neurokinin 3 Receptor Using Pharmacological Chaperones. Int J Mol Sci. 2022 Apr 21; 23(9).
-
Characterization of the Action of Tachykinin Signaling on Pulsatile LH Secretion in Male Mice. Endocrinology. 2021 08 01; 162(8).
-
Kisspeptin and Neurokinin B Signaling Network Underlies the Pubertal Increase in GnRH Release in Female Rhesus Monkeys. Endocrinology. 2017 10 01; 158(10):3269-3280.
-
Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the Women's Health Initiative Study. Menopause. 2017 03; 24(3):252-261.
-
Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial. J Clin Endocrinol Metab. 2016 11; 101(11):4313-4321.
-
Amygdala-Dependent Molecular Mechanisms of the Tac2 Pathway in Fear Learning. Neuropsychopharmacology. 2016 10; 41(11):2714-22.
-
Population Pharmacokinetic and Pharmacodynamic Modeling of AZD4901 and Simulation to Support Dose Selection for the Phase 2a Study. J Clin Pharmacol. 2016 08; 56(8):999-1008.
-
Rare coding variants and X-linked loci associated with age at menarche. Nat Commun. 2015 Aug 04; 6:7756.
-
Computational Analysis of Missense Variants of G Protein-Coupled Receptors Involved in the Neuroendocrine Regulation of Reproduction. Neuroendocrinology. 2016; 103(3-4):230-9.
-
Convergent QSAR studies on a series of NK3 receptor antagonists for schizophrenia treatment. J Enzyme Inhib Med Chem. 2016; 31(2):283-94.